<DOC>
	<DOCNO>NCT02708342</DOCNO>
	<brief_summary>RESEARCH METHODS Study Design Observational , Retrospective , Single-center , Single-arm Study patient treat raltegravir plus abacavir lamivudine .</brief_summary>
	<brief_title>Observational , Retrospective Analysis HIV-1 Infected Patients . ( ORASWIRAL )</brief_title>
	<detailed_description>Adult , male female HIV-1 infected subject , start antiretroviral regimen RALTEGRAVIR plus ABACAVIR LAMIVUDINE different antiretroviral regimen . Subject Selection : Inclusion Criteria All consecutive patient fulfil follow inclusion criterion consider : - HIV-1 infected patient , - age &gt; 18 year , - Human leukocyte antigen ( HLA ) B5701-negative - treatment-experienced patient viral suppression ( HIV-RNA &lt; 50 copies/mL ) , switch antiretroviral drug raltegravir plus abacavir lamivudine toxicity , convenience reason - switch Protease Inhibitor Raltegravir patient Abacavir lamivudine , switch Nucleoside analog reverse-transcriptase inhibitor ( NRTI ) combination abacavir lamivudine patient raltegravir , switch raltegravir plus abacavir lamivudine combination allow inclusion study - At least one viral load assess least start study regimen . Subject Selection : Exclusion Criteria - Documented drug-resistance virological failure integrase inhibitor , abacavir lamivudine start study regimen . - Pregnancy start study regimen . - HBsAg positive . Definitions Treatment Failure define occurrence Virological Failure change component study regimen reason treatment discontinuation time start consider treatment . Virological failure define occurrence two consecutive ( confirm ) viral load &gt; 50 copies/mL time follow-up . Variables/Information The following information extract Hospital database Department : - demographic ( age , sex , race ) - smoke - risk factor HIV infection - time HIV-1 diagnosis ( year ) - history AIDS diagnosis - hepatitis C virus ( HCV ) co-infection - hepatitis B virus ( HBV ) co-infection - presence co-morbidities ( include diabetes , hypertension , Cardio Vascular Diseases , Chronic kidney disease , cancer , etc ) - reason switch raltegravir + abacavir/lamivudine - time HIV-1 RNA &lt; 50 copies/mL switch - BMI - Hematology ( Hb , PLT ) - Creatinine - eGFR epidermal growth factor receptor ( Chronic kidney disease -EPI formula ) - Phosphorus - Calcium - Aspartate aminotransferase ( AST ) - ALT - FIB-4 ( liver index ) - alkaline phosphatase - total , direct , indirect bilirubin - proteinuria - hemoglobinuria - total , HDL- , LDL-cholesterol - triglyceride - glycemia - HIV-RNA - lymphocyte ( CD4+ , CD8+ , CD4/CD8 ratio ) since start raltegravir - previous antiretroviral regimen number previous antiretroviral agent . Data Sources The data source Infectious Diseases Database San Raffaele Hospital ( IDD-OSR ) , collect data patient follow outpatient clinic . Data collect routine clinical activity . Adverse Events occur initiation study treatment record classified drug-related accord severity . Power/Sample Size : 100 patient fulfil specify inclusion criterion available analysis . When estimate treatment efficacy proportion 80 % , sample size 100 subject produce two-sided 95 % confidence interval precision equal 8 % . Data Analysis Baseline characteristic enrol patient described median interquartile range frequency ( % ) , accord variable type . Follow-up count date start Raltegravir plus Abacavir lamivudine Treatment Failure last available visit , whichever first occur . Primary analysis Kaplan-Meier curve proportional hazard regression model use reference primary endpoint . Secondary analysis Trend time continuous variable ( height , weight , BMI , Hb , PLT , creatinine , eGFR , phosphorus , calcium , AST , ALT , FIB-4 , alkaline phosphatase , total , direct , indirect bilirubin , total , HDL- , LDL-cholesterol , triglyceride , glycaemia , HIV-RNA , CD4+ cell count ) assess ANOVA repeat measure univariate mixed linear model ( depend data structure ) ; chi-square test trend apply categorical variable ( proteinuria , hemoglobinuria ) . The non-parametric Wilcoxon sign rank test apply assess significant change continuous variable since baseline last available visit ; test change proportion baseline last available visit , McNemar test calculate . Relationships among continuous variable ( height , weight , BMI , Hb , PLT , creatinine , eGFR , phosphorus , calcium , AST , ALT , FIB-4 , alkaline phosphatase , total , direct , indirect bilirubin , total , HDL- , LDL-cholesterol , triglyceride , glycaemia , HIV-RNA , CD4+ cell count ) test calculate correlation coefficient ( Spearman rho , appropriate ) . Safety data analysis descriptive . Adverse Events , Serious Adverse Events tabulate , also accord severity , descriptive purpose . A two-sided alpha level 0.05 take reference detect statistical significance . All analysis perform Statistical Analysis Software , release 9.2 .</detailed_description>
	<criteria>Subject Selection : Inclusion Criteria All consecutive patient fulfil follow inclusion criterion consider : HIV1 infect patient , age &gt; 18 year , Human leukocyte antigen ( HLA ) B5701negative treatmentexperienced patient viral suppression ( HIVRNA &lt; 50 copies/mL ) , switch antiretroviral drug raltegravir plus abacavir lamivudine toxicity , convenience reason switch Protease Inhibitor Raltegravir patient Abacavir lamivudine , switch Nucleoside analog reversetranscriptase inhibitor ( NRTI ) combination abacavir lamivudine patient raltegravir , switch raltegravir plus abacavir lamivudine combination allow inclusion study At least one viral load assess least start study regimen . Subject Selection : Exclusion Criteria Documented drugresistance virological failure integrase inhibitor , abacavir lamivudine start study regimen . Pregnancy start study regimen . HBsAg positive .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>